Disposition of 1317956 shares by Brian Atwood of CERo Therapeutics at 1.77 subject to Rule 16b-3
| CERO Stock | 0.07 0.01 8.42% |
About 63% of CERo Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding CERo Therapeutics Holdings, suggests that many traders are alarmed. CERo Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in CERo Therapeutics Holdings,. Many technical investors use CERo Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
CERo |
Filed transaction by CERo Therapeutics Holdings, Director. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at macroaxis.com
Cash Flow Correlation
CERo Therapeutics' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the CERo Therapeutics' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
CERo Therapeutics Fundamental Analysis
We analyze CERo Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CERo Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CERo Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Beta
Beta Comparative Analysis
CERo Therapeutics is currently under evaluation in beta category among its peers. Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
CERo Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with CERo Therapeutics stock to make a market-neutral strategy. Peer analysis of CERo Therapeutics could also be used in its relative valuation, which is a method of valuing CERo Therapeutics by comparing valuation metrics with similar companies.
Peers
CERo Therapeutics Related Equities
| CTLT | Catalent | 0.05 | ||||
| XNET | Xunlei | 1.42 | ||||
| CSXXY | CarsalesCom | 1.67 | ||||
| WTI | WT Offshore | 2.27 | ||||
| AKAN | Akanda Corp | 3.23 |
Check out CERo Therapeutics Hype Analysis, CERo Therapeutics Correlation and CERo Therapeutics Performance. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CERo Therapeutics. If investors know CERo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CERo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.19) | Return On Assets (0.45) |
The market value of CERo Therapeutics is measured differently than its book value, which is the value of CERo that is recorded on the company's balance sheet. Investors also form their own opinion of CERo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CERo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CERo Therapeutics' market value can be influenced by many factors that don't directly affect CERo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CERo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if CERo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CERo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.